Oral Dissolving Strip vs Lozenge: Contact Time

Oral Dissolving Strip vs Lozenge: Contact Time

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

An oral dissolving strip and a lozenge both use the mouth, but they control mucosal contact very differently. A nicotine lozenge is designed to dissolve over 20 to 30 minutes, and users are told not to chew or swallow it (MedlinePlus). An orodispersible film is built for the opposite geometry: rapid hydration in about 30 to 60 seconds and directed contact with the mucosa (Hoffmann et al., 2011). In one buccal midazolam study, absolute bioavailability rose from 27.8 percent as a swallowed solution to 66.1 percent after 100 seconds of buccal contact. For MIHIYO Labs, that makes ODS the cleaner low-dose format.

Which works better: a lozenge or an oral dissolving strip?

For repeatable low-dose supplementation, I would usually choose the strip. A lozenge can stay in the mouth longer, but long residence is not the same thing as controlled residence. The lozenge keeps dissolving while the user sucks on it, shifts it around the mouth, and swallows saliva; a film is engineered to hydrate quickly, sit against the mucosa, and release a fixed unit dose with less user technique involved.124

That distinction matters more than people think. In formulation work, "contact time" is not just clock time. It is the combination of where the dose sits, how much surface area actually touches the mucosa, and how much of the dose is washed away into the gut before absorption can happen. I would rather control polymer weight, film thickness, and dissolution target than ask the user to nurse a candy-sized matrix for twenty minutes and hope the contact pattern stays useful.

Why contact time matters more than total mouth time

The oral mucosa is the tissue lining the cheek, tongue, and floor of the mouth. For the fraction of a dose that crosses that tissue, the major advantage is that it can reach the bloodstream before the liver sees it. That is what people mean by bypassing first-pass metabolism. But the bypass only applies to the part of the dose that actually penetrates the mucosa. Once the dissolved material is swallowed, it is ordinary gastrointestinal exposure again.5

This is the first reason I do not equate a lozenge with a strip. A lozenge is designed to dissolve slowly in saliva. MedlinePlus instructs nicotine-lozenge users not to chew or swallow the lozenge and to move it from side to side in the mouth while it dissolves over 20 to 30 minutes.1 That is useful advice, but it also tells you where the variability lives: the user is part of the dosage form. The dose is not fixed in one place, the saliva flow is not fixed, and the swallowed fraction is not fixed.

An oral dissolving strip is built around the opposite idea. Hoffmann and colleagues describe orodispersible films as thin polymer matrices that hydrate and disintegrate in saliva in roughly 30 to 60 seconds.2 Jacob and coauthors describe patch- and film-based buccal systems as platforms designed to maintain intimate association with the mucosa and prolong residence at the absorption site.4 In plain language, a film is supposed to put the dose where you want it, then stay there long enough for that placement to matter.

There is a second layer to this. A lozenge can stay in the mouth for much longer than a strip, but the extra time is mixed with constant dilution. The user sucks, saliva production rises, some drug dissolves locally, and some of that dissolved fraction is swallowed almost immediately. A film has less total mouth time, but it has more directed mouth time. For low-dose actives, that is usually the better trade.

How a lozenge and an oral dissolving strip create different kinds of mouth contact A lozenge dissolves slowly and mixes with saliva while the user moves it around the mouth, so more of the dose risks being swallowed during the dissolve. An oral dissolving strip hydrates quickly as a thin film against the mucosa, creating more directed local contact before the swallowed fraction forms. Lozenge Oral dissolving strip Slow dissolve in saliva User moves it side to side Thin film hydrates fast Placed in one geometry Saliva dilution rises Retained dose varies with use Directed mucosal contact Thin layer releases locally More swallowed fraction Mouth time is not fully useful time Part of first-pass skipped for the mucosal fraction Dose more likely to drift toward swallowing Dose held in a thinner, more directed contact layer

What the evidence says about lozenge vs strip performance

Dimension Lozenge Oral dissolving strip (ODS) Source
Contact profile Slow dissolve over 20 to 30 min; user moves it around the mouth and must avoid chewing/swallowing Rapid hydration in about 30 to 60 sec; thin film keeps the dose in one geometry MedlinePlus; Hoffmann et al., 2011
Dose precision Fixed active load, but retained dose depends on sucking pattern and swallowed saliva Fixed active load plus pharmacopeia-tested content uniformity across films MedlinePlus; Visser et al., 2015
Contact-time effect Longer mouth residence helps only if contact is effective Buccal exposure of 100 sec raised midazolam bioavailability from 27.8% to 66.1% vs swallowed solution Grass et al., 2021
Transmucosal delivery example Oral transmucosal fentanyl citrate lozenge is a valid clinical lozenge model, but not automatically the fastest mucosal format Fentanyl buccal film showed 71% absolute bioavailability with about 51% absorbed directly buccally Parikh et al., 2013; Vasisht et al., 2010
Portability and water-free use Pocketable, but larger, slow-dissolving, and more technique dependent Flat, dry, no-water unit dose designed for fast use MedlinePlus; Hoffmann et al., 2011
Examples showing how contact geometry changes oral transmucosal exposure A swallowed midazolam solution reached 27.8 percent absolute bioavailability, while 100 seconds of buccal exposure raised it to 66.1 percent. A fentanyl buccal film reached 71 percent absolute bioavailability, showing that directed buccal contact can produce far higher exposure than simple swallowing. 50% 75% 0% Swallowed solution 27.8% 100 sec buccal contact 66.1% Fentanyl buccal film 71.0% Nicotine lozenge use window 20-30 min dissolve Sources: Grass et al. 2021, Vasisht et al. 2010, MedlinePlus nicotine lozenges. The first three bars are bioavailability; the fourth is instructed dissolve time.

The table above is the short version. The deeper point is that the film wins by reducing variables, not by magically changing the biology of the mouth.

Contact profile. A lozenge offers more minutes in the mouth, but those minutes are not mechanically clean. The user is told to park it, move it, and avoid swallowing it.1 That is already an admission that saliva washout is a real issue. An ODS takes a shorter route: hydrate fast, spread thin, and release into a defined oral surface.2 For low-dose actives, I trust the simpler geometry more.

Dose precision. Both forms can be manufactured with a precise starting amount of active. The difference is what happens after dosing begins. Visser et al. showed that orodispersible films of several actives met European Pharmacopoeia requirements for uniformity of mass and content.3 That gives me confidence that the strip in the sachet is the strip I formulated. A lozenge still starts with a fixed load, but the dose actually retained against the mucosa depends on how the user sucks on it, how quickly saliva accumulates, and how much is swallowed during the dissolve. That is not a manufacturing failure. It is a route-mechanics issue.

Contact-time effect. The cleanest paper on this is not a lozenge paper at all. Grass et al. used microdosed midazolam to show that buccal exposure time itself changes absolute bioavailability: 27.8 percent as a swallowed drinking solution versus 66.1 percent after 100 seconds of buccal contact.6 That is the principle I care about. More contact can help. But it helps only when the contact is directed and sustained at the mucosa. That is why I am careful not to translate "longer dissolve" into "better absorption" automatically.

Clinical transmucosal examples. Fentanyl is useful here because the approved dosage forms span the exact oral-delivery question. Parikh et al. compared fentanyl sublingual spray with oral transmucosal fentanyl citrate, the classic medicated lozenge used in oncology pain management.7 Vasisht et al. reported that fentanyl buccal soluble film reached 71 percent absolute bioavailability, with roughly 51 percent of the dose absorbed directly through the buccal mucosa and the remainder swallowed.8 What I infer from those papers is not that every film beats every lozenge. It is that the clinically meaningful question is where the dose sits and what fraction gets swallowed during the ride.

Portability and use pattern. Lozenges are portable enough. I do not think portability is the decisive row in this comparison. The real use-pattern difference is session length. A lozenge asks for a multi-minute interaction and a fairly patient mouthfeel. A strip asks for placement and a short dissolve. For an evening melatonin dose or a small daytime nootropic dose, that shorter, flatter ritual is easier to repeat consistently.

What this means for MIHIYO products

This is where my own formulation bias comes in. For products like Sleep-Support ODS and Mood-Boost ODS, I am usually dealing with modest active loads where precision matters more than payload. I am not trying to create a throat-soothing confection or a prolonged local effect. I am trying to give the user a repeatable low dose, with a defined mouthfeel and a short, predictable use window.

That is why I choose the strip platform over a lozenge. A film lets me control the matrix mass tightly, target a brief dissolution window, and keep the experience close to the same from one unit to the next. A lozenge can absolutely work. It is an established pharmaceutical dosage form. But it asks the customer to participate in the retention step more actively than I want for these products.

I also do not think sugar content is the strongest scientific argument here, and I want to be explicit about that. Some lozenges are sugar-free, so I would not make a sweeping "strip good, lozenge sugary" claim. The better formulation argument is sweetener burden and dosage geometry. A lozenge is a larger dissolving mass that has to stay palatable for minutes. A strip is a thin dose carrier designed to disappear quickly. That difference affects mouthfeel, saliva response, and how much user patience the format demands.

Every study in this article is on independent clinical or formulation systems, not on MIHIYO products. We do not have a head-to-head human pharmacokinetic study comparing a MIHIYO strip to a matched lozenge. The evidence here is route science and dosage-form engineering, applied honestly.

Where a lozenge can be the better choice

I would not use this article to say a lozenge is obsolete. That would be sloppy.

If the goal is prolonged local action in the mouth or throat, a lozenge makes obvious sense. The whole design is built around a long dissolve. That can be useful when the product is supposed to linger locally rather than move on quickly to systemic circulation.

If the active load is larger than I want to put into a thin film, a lozenge may also be easier to formulate. Films are elegant at low to moderate payloads, but they do not solve every loading problem. The more active I ask a film to carry, the more I have to fight thickness, brittleness, taste, and dissolution speed.

A lozenge can also suit users who simply dislike the feel of a strip on the tongue or cheek. I do not dismiss that. Compliance is part of formulation reality. A technically superior delivery path that a customer avoids is not superior in practice.

The honest answer, then, is this: the lozenge's strength is extended presence. The strip's strength is controlled presence. For the kind of low-dose, fast-use supplements I formulate, controlled presence is usually the one that matters more.

The bottom line

In an oral dissolving strip vs lozenge comparison, the deciding issue is not which form stays in the mouth longer. It is which form controls contact better. Lozenges can dissolve for 20 to 30 minutes and still lose a meaningful fraction of dose to swallowing, while an ODS is engineered to hydrate in about 30 to 60 seconds and hold a fixed, thin dose against the mucosa.12 The midazolam buccal-contact study makes the pharmacology clear: effective contact can more than double systemic exposure versus simple swallowing.6 For MIHIYO Labs, that is why I prefer the strip for repeatable low-dose delivery.

References

  1. MedlinePlus. Nicotine Lozenges: MedlinePlus Drug Information. U.S. National Library of Medicine. <https://medlineplus.gov/druginfo/meds/a606002.html>
  2. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. PMID: 21284577. DOI: 10.1517/17425247.2011.553217. <https://pubmed.ncbi.nlm.nih.gov/21284577/>
  3. Visser JC, Woerdenbag HJ, Crediet S, Gerrits E, Lesschen MA, Hinrichs WLJ, Breitkreutz J, Frijlink HW. Orodispersible films in individualized pharmacotherapy: the development of a formulation for pharmacy preparations. Int J Pharm. 2015;478(1):155-163. PMID: 25448577. DOI: 10.1016/j.ijpharm.2014.11.013. <https://pubmed.ncbi.nlm.nih.gov/25448577/>
  4. Jacob S, Nair AB, Patil A, Boddu SHS. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics. 2021;13(8):1206. PMID: 34452167. DOI: 10.3390/pharmaceutics13081206. <https://pubmed.ncbi.nlm.nih.gov/34452167/>
  5. Bartlett JA, van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13(4):1110-1115. PMID: 22936407. DOI: 10.1208/s12249-012-9839-7. <https://pubmed.ncbi.nlm.nih.gov/22936407/>
  6. Grass J, Rose P, Burhenne J, et al. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol. 2021;61(4):532-539. PMID: 32976642. DOI: 10.1002/jcph.1751. <https://pubmed.ncbi.nlm.nih.gov/32976642/>
  7. Parikh N, Goskonda V, Chavan A, Dillaha L. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. Clin Ther. 2013;35(3):236-243. PMID: 23497761. <https://pubmed.ncbi.nlm.nih.gov/23497761/>
  8. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble Film. Pain Med. 2010;11(7):1017-1023. PMCID: PMC2955962. DOI: 10.1111/j.1526-4637.2010.00875.x. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2955962/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.